127 research outputs found
Human hypertrophic cardiomyopathy : from electrophysiological insights to pharmacological strategies : [abstract]
The Funny Current in Cardiac Non-Pacemaker Cells: Functional Role and Pharmacological Modulation
Action Potential Modelling Predicts Electrophysiological and Pharmacological Features of Human Embryonic Stem Cell-derived Cardiomyocytes
Pharmacological inhibition of serine proteases to reduce cardiac inflammation and fibrosis in atrial fibrillation
Losartan ameliorates diabetic vascular hyper-reactivity to angiotensin II by reducing ROCK1 expression and activity
Pharmacological perspectives in sarcopenia: A potential role for renin-angiotensin system blockers?
Sarcopenia represents a major health problem highly prevalent in elderly and age-related chronic diseases. Current pharmacological strategies available to prevent and reverse sarcopenia are largely unsatisfactory thus raising the need to identify novel targets for pharmacological intervention and possibly more effective and safe drugs. This review highlights the current knowledge of the potential benefits of renin-angiotensin system blockade in sarcopenia and discuss the main mechanisms underlying the effects
Functional Expression and Subcellular Localization of f-Channels in Native Human and hESC-Derived Cardiomyocytes
Losartan counteracts the hyper-reactivity to angiotensin II and ROCK1 over-activation in aortas isolated from streptozotocin-injected diabetic rats
<p>Abstract</p> <p>Background</p> <p>In streptozotocin-injected rats (STZ-rats), we previously demonstrated a role for angiotensin II (AT-II) in cardiac remodelling and insulin resistance partially counteracted by <it>in vivo </it>treatment with losartan, an AT-II receptor antagonist.</p> <p>We now aimed to investigate the effect of treating diabetic STZ-rats with losartan on diabetes vascular response to vasoconstrictors.</p> <p>Methods</p> <p>Male Wistar rats were randomly divided in four groups, two of them were assigned to receive losartan in the drinking water (20 mg/kg/day) until the experiment ending (3 weeks afterward). After 1 week, two groups, one of which receiving losartan, were injected in the tail vein with citrate buffer (normoglycemic, N and normoglycemic, losartan-treated, NL). The remaining received a single injection of streptozotocin (50 mg/kg in citrate i.v.) thus becoming diabetic (D) and diabetic losartan-treated (DL). Plasma glycaemia and blood pressure were measured in all animals before the sacrifice (15 days after diabetes induction).</p> <p>In aortic strips isolated from N, NL, D and DL rats we evaluated i) the isometric concentration-dependent contractile response to phenylephrine (Phe) and to AT-II; ii) the RhoA-kinase (ROCK1) activity and expression by enzyme-immunoassay and Western blot respectively.</p> <p>Key results</p> <p>The concentration-dependent contractile effect of Phe was similar in aortas from all groups, whereas at all concentrations tested, AT-II contraction efficacy was 2 and half and 1 and half times higher in D and DL respectively in comparison with N and NL. AT-II contracture was similarly reduced in all groups by AT-II receptor antagonists, irbesartan or irbesartan plus PD123319. HA-1077 (10 μM), an inhibitor of ROCK1 activity, reduced AT-II efficacy (Δmg/mg tissue w.w.) by -3.5 ± 1.0, -4.6 ± 1.9, -22.1 ± 2.2 and -11.4 ± 1.3 in N, NL, D and DL respectively). ROCK1 activity and expression were higher in D than in N/NL and DL aortas.</p> <p>Conclusion and implications</p> <p>Aortas isolated from STZ-rats present hyper-contracture to AT-II mainly dependent on the up-regulation of ROCK1 expression/activity. In vivo losartan treatment partially corrects AT-II hyper-contracture, limiting the increase in ROCK1 expression/activity. These data offer a new molecular mechanism supporting the rationale for using losartan in the prevention of diabetic vascular complications.</p
Regulation of intracellular Na+ in health and disease: pathophysiological mechanisms and implications for treatment
- …